TRV027: Phase IIb ongoing

A DSMB recommended continuation of the double-blind Phase IIb BLAST-AHF trial comparing 1, 5 and 25 mg/hour IV TRV027 given continuously for 48-96 hours plus standard therapy vs. placebo plus standard...